Trial · NCT03468426
Adverse events3,333
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 3,333
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Part 1 - BI 836880 360 mg | 1 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1 - BI 836880 500 mg | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1 - BI 836880 720 mg | 1 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 - Cohort A, 2nd line NSCLC | 5 | 42 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 - Cohort B, 3rd line NSCLC | 5 | 40 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 - Cohort C, SCLC | 0 | 31 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 - Cohort D, glioblastoma | 0 | 31 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 - Cohort E, Melanoma | 3 | 32 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 - Cohort F, 2nd line Hepatocellular Carcinoma | 2 | 30 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 - Cohort G, 1st line Hepatocellular Carcinoma | 1 | 31 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 - Cohort H, 2nd line HCC - atezolizumab in combination with bevacizumab failures | 0 | 1 | |
| other | Hypothyroidism | Endocrine disorders | Part 1 - BI 836880 360 mg | 0 | 3 | |
| other | Hypothyroidism | Endocrine disorders | Part 1 - BI 836880 500 mg | 0 | 3 | |
| other | Hypothyroidism | Endocrine disorders | Part 1 - BI 836880 720 mg | 1 | 8 | |
| other | Hypothyroidism | Endocrine disorders | Part 2 - Cohort A, 2nd line NSCLC | 4 | 42 | |
| other | Hypothyroidism | Endocrine disorders | Part 2 - Cohort B, 3rd line NSCLC | 1 | 40 | |
| other | Hypothyroidism | Endocrine disorders | Part 2 - Cohort C, SCLC | 2 | 31 | |
| other | Hypothyroidism | Endocrine disorders | Part 2 - Cohort D, glioblastoma | 4 | 31 | |
| other | Hypothyroidism | Endocrine disorders | Part 2 - Cohort E, Melanoma | 2 | 32 | |
| other | Hypothyroidism | Endocrine disorders | Part 2 - Cohort F, 2nd line Hepatocellular Carcinoma | 5 | 30 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03468426/events